Cellution Biologics Inc. said it acquired the SimpliDerm hydrated human acellular dermal matrix business from Elutia Inc. for $8 million at closing, with up to an additional $3 million payable over the next 18 months based on transition and commercial milestones.
The SimpliDerm portfolio, which includes products designed for soft tissue repair and reconstruction, adds a new surgical category to Cellution’s existing wound care, ocular repair and other surgical applications. The acquisition also grants Cellution access to established U.S. market relationships with surgeons, hospitals, group purchasing organizations and integrated delivery networks.
Cellution, headquartered in Roswell, Georgia, said the deal supports its strategy to expand its human tissue-based portfolio and strengthen capabilities across surgical markets. Shiva Arjunon, president of Cellution Biologics, stated the acquisition marks an important step in the company’s growth plan.
Elutia, listed on the NASDAQ under the ticker ELUT, did not disclose terms of the transaction beyond the $8 million upfront payment and potential milestone payments.
